Melanoma clinical trials in Ames, IA
3 studies for Melanoma are looking for participants at sites in and around Ames (within about 30 miles). Open a study to see who can join and how to contact the study team.
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RecruitingPhase 2
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- McFarland Clinic - Boone, Boone · 13 mi away
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN32 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Salt Lake City, UT21 studies
- Columbus, OH21 studies
- Atlanta, GA21 studies
- St. Louis, MO20 studies
Other studies in Ames
- Prostate Cancer7 studies
- Lung Cancer7 studies
- Non-Small Cell Lung Cancer6 studies
- Kidney Cancer (Renal Cell Carcinoma)5 studies
- Bladder Cancer4 studies
- Breast Cancer4 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Hypopharyngeal Cancer3 studies
- Laryngeal Cancer3 studies
- Oral Cancer3 studies
- Chronic Lymphocytic Leukemia3 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.